Itromac 200mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its therapeutic effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Itromac 200mg is primarily prescribed for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. The capsule formulation facilitates oral administration, ensuring adequate bioavailability and patient compliance. Dosage and duration of therapy should be individualized based on the type and severity of infection, as well as patient response. Itromac 200mg should be used with caution in patients with hepatic impairment and is contraindicated in those with known hypersensitivity to itraconazole or other azole antifungals. Potential drug interactions, particularly with medications metabolized by the cytochrome P450 system, must be carefully evaluated to avoid adverse effects. Common side effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy.